Newsroom
May 7, 2020
Dr. Thomas Patterson, chief of the Division of Infectious Disease, was a guest on KTSA’s Jack Riccardi Show. Dr. Patterson discussed the new anti-viral drug, remdesivir, for the sickest COVID-19 patients. Dr. Patterson is leading a local study site in the clinical trial testing the drug, which just received emergency authorization from the FDA. He […]
May 7, 2020
Dr. Fred Campbell, an internal medicine doctor in the Department of General and Hospital Medicine, answered questions about COVID-19 on KTSA’s Jack Riccardi Show. Topics included low oxygen saturation, lung condition of COVID-19 survivors and antibody treatments. Listen below:
May 6, 2020
SARS-CoV-2 survivors have an important asset: antibodies against it. Studying samples from these individuals will help a team at the Long School of Medicine to understand which antibodies best neutralize the coronavirus. This will be important in developing an effective vaccine against the infection. Read the full story.
May 6, 2020
Dr. Thomas Patterson, chief of the Division of Infectious Diseases, explained the implications of the FDA fast-tracking emergency authorization of the new anti-viral drug, remdesivir. Listen to the interview.
May 5, 2020
Dr. Thomas Patterson, chief of the Division of Infectious Diseases, explained the implications of the FDA fast-tracking emergency authorization of the new anti-viral drug, remdesivir. Read the full story.
May 4, 2020
Drs. Thomas Patterson, chief of the Division of Infectious Diseases, and Jason Bowling, Infectious Diseases, explained the implications of the FDA fast-tracking emergency authorization of the new anti-viral drug, remdesivir, as the new standard of care for hospitalized COVID-19 patients. Read and watch the full story.